Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

The grading of gliomas based on histological features has been a subject of debate for
several decades. A consensus has not yet been reached because of technical limitations …

Background Significant advances in the molecular profiling of gliomas, led the 2016 World
Health Organization (WHO) Classification to include, for the first-time, molecular biomarkers …

Abstract The World Health Organization (WHO) classification of central nervous system
(CNS) tumors was revised in 2016 with a basis on the integrated diagnosis of molecular …

The identification of distinct genetic and epigenetic profiles in different types of gliomas has
revealed novel diagnostic, prognostic, and predictive molecular biomarkers for refinement of …

Many patients with malignant gliomas do not respond to alkylating agent chemotherapy.
Alkylator resistance of glioma cells is mainly mediated by the DNA repair enzyme O 6 …

The identification of molecular genetic biomarkers considerably increased our current
understanding of glioma genesis, prognostic evaluation, and treatment planning. In …

Background Recent studies have proposed several gene signatures as biomarkers for
different grades of gliomas from various perspectives. However, most of these genes can …

Abstract The current World Health Organization (WHO) classification of human gliomas is
mainly based on morphology. However, it has limitations in prognostic prediction. We …

Since the discovery that IDH1/2 mutations confer a significantly better prognosis in
astrocytomas, much work has been done to identify other molecular signatures to help …